Heart failure today.
In summary, we are at a very exciting stage because we had all the complex methods shown to us that could be used for further studies. We have also been introduced to the concept that ibopamine is a type of drug that warrants further studies which are going to be very carefully planned to utilize all the very sophisticated armamentarium we now have at our command. Finally, I would like to thank the chairmen of the various sessions for allowing the meeting to flow so smoothly: Prof. Hugenholtz, Bounhoure, Kulbertus, Dalla Volta and Bricaud and Dr. Lopez Sendon. I would like to thank all the speakers. I would also like to thank the audience, because without you we would not be here. Thank you very much indeed.
Opie
L H
LH
Heart Research Unit, University of Cape Town, Medical School, Observatory, South Africa.
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D011788:Quality of Life
D002316:Cardiotonic Agents